BTIG Research Issues Positive Forecast for Natera (NASDAQ:NTRA) Stock Price

Key Points

• BTIG Research has increased its price target for Natera's stock from $200.00 to $210.00, indicating a potential upside of 9.33% from the current price, and has a "buy" rating on the stock.
• Natera's stock has experienced a positive trading day, increasing by $4.06 to reach $192.08, with a market capitalization of approximately $26.36 billion.
• Despite a report of quarterly earnings showing a loss of ($0.74) per share, Natera's revenue rose 32.2% year-over-year to $546.60 million, surpassing analysts' estimates.

Natera (NASDAQ:NTRA - Get Free Report) had its price objective boosted by equities research analysts at BTIG Research from $200.00 to $210.00 in a research note issued on Thursday,Benzinga reports. The firm currently has a "buy" rating on the medical research company's stock. BTIG Research's target price would suggest a potential upside of 9.33% from the stock's current price.

NTRA has been the subject of a number of other research reports. Evercore ISI raised Natera to a "strong-buy" rating and set a $170.00 price objective for the company in a research report on Monday, July 28th. Zacks Research lowered Natera from a "hold" rating to a "strong sell" rating in a report on Monday. Royal Bank Of Canada set a $268.00 target price on Natera and gave the stock an "outperform" rating in a report on Tuesday, September 2nd. Stephens reissued an "overweight" rating and issued a $183.00 target price on shares of Natera in a report on Friday, August 15th. Finally, Barclays reissued an "overweight" rating and issued a $210.00 target price (up previously from $190.00) on shares of Natera in a report on Friday, August 8th. One research analyst has rated the stock with a Strong Buy rating, sixteen have given a Buy rating, one has issued a Hold rating and two have assigned a Sell rating to the stock. According to MarketBeat.com, Natera presently has a consensus rating of "Moderate Buy" and an average price target of $197.59.

Natera Stock Performance

Shares of NTRA traded up $4.06 on Thursday, reaching $192.08. The stock had a trading volume of 378,253 shares, compared to its average volume of 1,420,236. The firm has a market capitalization of $26.36 billion, a price-to-earnings ratio of -100.52 and a beta of 1.74. The company has a 50-day simple moving average of $169.97 and a 200-day simple moving average of $159.37. Natera has a 12-month low of $117.27 and a 12-month high of $196.63.

Natera (NASDAQ:NTRA - Get Free Report) last posted its quarterly earnings data on Thursday, August 7th. The medical research company reported ($0.74) earnings per share for the quarter, missing analysts' consensus estimates of ($0.60) by ($0.14). Natera had a negative net margin of 12.89% and a negative return on equity of 22.22%. The company had revenue of $546.60 million for the quarter, compared to the consensus estimate of $476.84 million. During the same period last year, the business earned ($0.30) EPS. The firm's quarterly revenue was up 32.2% on a year-over-year basis. Natera has set its FY 2025 guidance at EPS. On average, analysts expect that Natera will post -1.49 EPS for the current fiscal year.

Insider Transactions at Natera

In related news, CFO Michael Burkes Brophy sold 602 shares of Natera stock in a transaction on Tuesday, October 21st. The stock was sold at an average price of $187.95, for a total value of $113,145.90. Following the completion of the sale, the chief financial officer owned 70,109 shares of the company's stock, valued at $13,176,986.55. The trade was a 0.85% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, insider John Fesko sold 339 shares of the business's stock in a transaction dated Tuesday, October 21st. The shares were sold at an average price of $187.95, for a total value of $63,715.05. Following the sale, the insider directly owned 152,408 shares of the company's stock, valued at $28,645,083.60. This represents a 0.22% decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 70,276 shares of company stock worth $10,794,948. 5.63% of the stock is currently owned by insiders.

Institutional Trading of Natera

Several hedge funds have recently bought and sold shares of the stock. Vanguard Group Inc. grew its holdings in Natera by 2.3% during the second quarter. Vanguard Group Inc. now owns 12,676,653 shares of the medical research company's stock valued at $2,141,594,000 after purchasing an additional 282,826 shares during the period. JPMorgan Chase & Co. grew its holdings in Natera by 44.3% during the second quarter. JPMorgan Chase & Co. now owns 10,625,785 shares of the medical research company's stock valued at $1,795,125,000 after purchasing an additional 3,263,822 shares during the period. Price T Rowe Associates Inc. MD grew its holdings in Natera by 56.3% during the first quarter. Price T Rowe Associates Inc. MD now owns 10,537,743 shares of the medical research company's stock valued at $1,490,144,000 after purchasing an additional 3,795,315 shares during the period. Geode Capital Management LLC grew its holdings in Natera by 7.0% during the second quarter. Geode Capital Management LLC now owns 2,552,725 shares of the medical research company's stock valued at $430,640,000 after purchasing an additional 166,768 shares during the period. Finally, Invesco Ltd. grew its holdings in Natera by 13.7% during the first quarter. Invesco Ltd. now owns 2,035,979 shares of the medical research company's stock valued at $287,908,000 after purchasing an additional 245,719 shares during the period. Institutional investors own 99.90% of the company's stock.

About Natera

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.